Brain and Central Nervous System Tumors
418
1
6
301
Key Insights
Highlights
Success Rate
88% trial completion (above average)
Published Results
55 trials with published results (13%)
Research Maturity
301 completed trials (72% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
9.8%
41 terminated out of 418 trials
88.0%
+1.5% vs benchmark
8%
32 trials in Phase 3/4
18%
55 of 301 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 301 completed trials
Clinical Trials (418)
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma
Radiation Therapy With Concomitant and Adjuvant Temozolomide Versus Radiation Therapy With Adjuvant PCV Chemotherapy in Patients With Anaplastic Glioma or Low Grade Glioma
Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma
Study of Stored Tumor Samples in Young Patients With Brain Tumors
Radiation Therapy With or Without Temozolomide in Treating Patients With Low-Grade Glioma
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma
Study of MT027 in Patients with Brain, Meninges, and Spinal Cord Metastatic Solid Tumors
Observation or Radiation Therapy With or Without Combination Chemotherapy in Treating Patients With Low-Grade Glioma
Temozolomide and Radiation Therapy in Treating Patients With Gliomas
Cilengitide and Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases From Lung Cancer
Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer
Treatment of Patients With Newly Diagnosed Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumor, or Atypical Teratoid Rhabdoid Tumor
AXL Inhibitor BGB324 in Treating Participants With Recurrent Glioblastoma Undergoing Surgery
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
Interferon Alfa in Treating Patients With Recurrent Unresectable Meningiomas and Malignant Meningiomas
Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors
Phase III Trial of Anaplastic Glioma Without 1p/19q Loss of Heterozygosity (LOH)
Observation or Radiation Therapy in Treating Patients With Grade I, Grade II, or Grade III Meningioma
Radiation Therapy With or Without Temozolomide in Treating Older Patients With Newly Diagnosed Glioblastoma Multiforme